McKesson Corporation is consistently attracting investor attention with its stock gaining 18% Year-to-Date (YTD), driven by a potential stake negotiation in Florida Cancer Specialists and delivering a soaring earnings guidance. Despite grappling with supply and demand issues affecting its weight-loss drugs and a consequential dip in its quarterly revenue, the company’s overall performance remains promising, largely due to its robust pharmacy management software & services. Notably,
McKesson is 88% owned by institutional shareholders, reflecting investor’s confidence. Factors cementing its long-term potential include strong revenue growth and raised full-year guidance amidst mixed fiscal 2024 results. However, the recent fiscal Q1 revenue miss led to a temporary stock fall. Currently, the company seems set for a prosperous year, with a 25% YTD gain, positive Q3 earnings, and a raised FY24 EPS outlook. While the company is performing well, McKesson's intrinsic value is potentially 82% above its current share price, indicating room for potential growth. Despite a recent market slip, McKesson continues to perform well in the stock market, reporting 10% revenue growth in Q2 fiscal 2024 and again raising full-year guidance.
Mckesson Corporation MCK News Analytics from Wed, 01 Nov 2023 07:00:00 GMT to Fri, 23 Aug 2024 20:03:56 GMT -
Rating 7
- Innovation 8
- Information 7
- Rumor -7
